Genitourinary Cancers | Specialty

OncLive News Network On Location: GU 2020 Day 2

February 14th 2020

OncLive News Network On Location: GU 2020 Day 1

February 14th 2020

Ilixadencel Added to Sunitinib Shows Positive OS Trend in RCC

February 13th 2020

The addition of the off-the-shelf cancer immune primer ilixadencel to sunitinib trended toward a benefit in overall survival compared with sunitinib alone as a first-line treatment for patients with newly diagnosed metastatic renal cell carcinoma.

NICE Recommends Against Frontline Pembrolizumab/Axitinib in Advanced RCC

February 13th 2020

The United Kingdom’s National Institute for Health and Care Excellence has chosen to not recommend the combination of pembrolizumab and axitinib for use in treatment-naïve adult patients with advanced renal cell carcinoma.

Dr. McDermott on Toxicities of Immunotherapy Combinations in RCC

February 12th 2020

David F. McDermott, MD, discusses the toxicities associated with immunotherapy combinations in renal cell carcinoma.

Dr. Pal on the Potential Use of PARP Inhibitors in RCC

February 11th 2020

Sumanta Kumar Pal, MD, discusses the potential use of PARP inhibitors in renal cell carcinoma.

Dr. Braun on Frontline Immunotherapy in Advanced RCC

February 7th 2020

David A. Braun, MD, PhD, physician at Dana-Farber Cancer Institute and instructor of medicine at Harvard Medical School, discusses the use of immunotherapy in the frontline treatment of patients with advanced renal cell carcinoma (RCC).

Dr. Vaishampayan on the Shifting Role of Cytoreductive Nephrectomy in RCC

February 6th 2020

Ulka Vaishampayan, MD, discusses the shifting role of cytoreductive nephrectomy in renal cell carcinoma.

New Chapter Opens in Bladder Cancer Treatment

February 5th 2020

For years, the treatment landscape for bladder cancer was defined by lackluster consistency: There were no advances. However, the drought ended with the introduction of immune checkpoint blockade, according to Charles G. Drake, MD, PhD.

ASCO Names Refinement of Surgical Treatment of Cancer as Advance of the Year

February 5th 2020

Following significant progress made in the development of novel systemic therapies for patients with cancer, the role of surgery in oncology continues to evolve. To this end, ASCO has selected the refinement of surgical treatment of cancer as its Advance of the Year.

Dr. Beckermann on Investigational Treatment Strategies in mRCC

February 4th 2020

Kathryn E. Beckermann, MD, PhD, discusses investigational treatment strategies in metastatic renal cell carcinoma.

Dr. Alva on Results of the CABOSUN Trial in RCC

February 4th 2020

Ajjai Shivaram Alva, MBBS, discusses the results of the CABOSUN trial in renal cell carcinoma.

Dr. Braun on Evolution of Immunotherapy in Advanced Renal Cell Carcinoma

January 30th 2020

David A. Braun, MD, PhD, discusses the evolution of immunotherapy in advanced renal cell carcinoma.

Dr. Alva on TKI Monotherapy and Combinations for RCC

January 22nd 2020

Ajjai Shivaram Alva, MBBS, discusses TKI monotherapy and in combination with immunotherapy for patients with renal cell carcinoma.

FDA Approvals Boost Competition in Treatment Landscapes

January 18th 2020

Therapeutic developments in cancer were rewarded with a wave of approvals in 2019.

Dr. Bochner on Standardizing Molecular Profiling in Bladder Cancer

January 11th 2020

Bernard H. Bochner, MD, FACS, discusses the potential standardization of molecular profiling in bladder cancer.

Immunotherapy Combos Emerge as Standard Frontline Treatment in Advanced RCC

January 10th 2020

David F. McDermott, MD, discusses developments in the frontline setting for the treatment of patients with advanced renal cell carcinoma.

PARP Inhibitors, Vaccines, and Combos Spark Excitement in mRCC

January 10th 2020

Sumanta Kumar Pal, MD, discusses novel strategies on the horizon in renal cell carcinoma.

Dr. Flaig on Immune Checkpoint Inhibitors in Advanced Bladder Cancer

January 10th 2020

Thomas W. Flaig, MD, discusses the utility of immune checkpoint inhibitors in advanced bladder cancer.

Expert Explains Clinical Developments With Cytoreductive Nephrectomy in mRCC

January 9th 2020

Ulka Vaishampayan, MD, discusses the historical management of patients with metastatic renal cell carcinoma and how advances with systemic therapy have impacted the sequencing of cytoreductive nephrectomy in the treatment paradigm.